https://www.globenewswire.com/news-release/2022/08/15/2498154/18362/en/Latest-Research-Evaluating-VASCEPA-VAZKEPA-icosapent-ethyl-and-Subgroups-from-the-REDUCE-IT-Landmark-Outcomes-Trial-to-be-Presented-at-the-European-Society-of-Cardiology-ESC-Congre.html
0
0
Latest Research Evaluating VASCEPA®/VAZKEPA (icosapent ethyl) and Subgroups from the REDUCE-IT® Landmark Outcomes Trial to be Presented at the European Society of Cardiology (ESC) Congress - GlobeNewswire
8/15/22 at 5:00am
Organization
GlobeNewswire
Author
Amarin Corporation plc
Details
50 words
Summarize
Health Landmark Outcomes Trial Research Evaluating VASCEPA VAZKEPA ethyl Subgroups European Society of Cardiology GLOBE NEWSWIRE Dublin Ireland BRIDGEWATER New Jersey Amarin Corporation plc Nasdaq AMRN
DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or...
Create an account or login to join the discussion